⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4112851 | 0.77 | — | — | |
| SCHEMBL4100698 | 0.74 | — | — | |
| SCHEMBL227555 | 0.62 | — | — | |
| SCHEMBL1540794 | 0.60 | — | — | |
| SCHEMBL1113802 | 0.60 | — | — | |
| SCHEMBL6024718 | 0.60 | — | — | |
| SCHEMBL374036 | 0.58 | — | — | |
| SCHEMBL2275919 | 0.55 | — | — | |
| SCHEMBL1474 | 0.51 | — | — | |
| SCHEMBL102953 | 0.51 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981703-B2 | Polynucleotide constructs | SIRIUS THERAPEUTICS, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| CN-117813281-A | Continuous flow process for the production of cationic lipids | 马克斯·普朗克科学促进学会 | 2024-04-02 | — | — | CN | disclosed |
| EP-4341241-A1 | CONTINUOUS FLOW PROCESS FOR PRODUCTION OF CATIONIC LIPIDS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-03-27 | — | — | EP | disclosed |
| WO-2023250427-A2 | FORMULATIONS FOR MODULATING MYC EXPRESSION | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023250429-A2 | COMBINATION THERAPIES COMPRISING MYC MODULATION | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230321083-A1 | Inhibitors of GPR174 and Uses Thereof | OMEROS CORP (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | disclosed |
| US-20230242567-A1 | CHIRAL PHOSPHORAMIDITE AUXILIARIES AND METHODS OF THEIR USE | SIRIUS THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| EP-4183770-A1 | CONTINUOUS FLOW PROCESS FOR PRODUCTION OF CATIONIC LIPIDS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-05-24 | — | — | EP | disclosed |
| US-11597744-B2 | Chiral phosphoramidite auxiliaries and methods of their use | SIRIUS THERAPEUTICS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| EP-1990365-A1 | Resin composition | Sony Corporation (JP) | 2008-11-12 | — | — | EP | disclosed |
| US-20070224672-A1 | Method of Identifying Inhibitors of DHODH | LEBAN JOHANN | 2007-09-27 | — | — | US | disclosed |
| US-7247736-B2 | Method of identifying inhibitors of DHODH | 4SC AG (DE) | 2007-07-24 | — | — | US | disclosed |
| US-20070027193-A1 | Method of identifying inhibitors of DHODH | 4SC AG (DE) | 2007-02-01 | — | — | US | disclosed |
| US-20060167134-A1 | Resin composition and process for producing resin molding | Lerner, David, Littenberg, Krumholz & Mentlik, LLP | 2006-07-27 | — | — | US | disclosed |
| EP-1591487-A1 | RESIN COMPOSITION AND PROCESS FOR PRODUCING RESIN MOLDING | Sony Corporation (JP) | 2005-11-02 | — | — | EP | disclosed |
| EP-1581478-A1 | DHODH-INHIBITORS AND METHOD FOR THEIR IDENTIFICATION | 4SC AG (DE) | 2005-10-05 | — | — | EP | disclosed |
| EP-1538184-A1 | RESIN COMPOSITION | Sony Corporation (JP) | 2005-06-08 | — | — | EP | disclosed |
| US-20050014870-A1 | Resin composition | SONY CORPORATION (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004056747-A1 | DHODH-INHIBITORS AND METHOD FOR THEIR IDENTIFICATION | 4SC AG (DE) | 2004-07-08 | — | — | WO | disclosed |